Vavelta: Phase II started

Intercytex began a placebo-controlled, U.K. Phase II trial to evaluate a single series of intradermal Vavelta for 3 months in 20 patients. Patients will receive 0.25 mL of 20 x10 6 cells/mL ICX-RHY pe...